HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $17 to $11.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $17 to $11.